STOCK TITAN

HIKMA PHARMS PLC S/ADR - HKMPY STOCK NEWS

Welcome to our dedicated page for HIKMA PHARMS PLC S/ADR news (Ticker: HKMPY), a resource for investors and traders seeking the latest updates and insights on HIKMA PHARMS PLC S/ADR stock.

Hikma Pharmaceuticals PLC (Hikma) is a multinational pharmaceutical company headquartered in the UK, with a global presence across North America, the Middle East and North Africa (MENA), and Europe. With over 45 years of experience, Hikma focuses on creating high-quality medicines and making them accessible to millions of people. The company transforms cutting-edge science into innovative solutions that improve people's lives. Hikma is committed to providing a broad range of branded and non-branded generic medicines, shaping a healthier world for all communities. Through collaborations, partnerships, and ventures, Hikma is at the forefront of advancing precision medicine and healthcare technologies globally.

Rhea-AI Summary

Hikma Pharmaceuticals has completed its acquisition of Custopharm for an initial $375 million, enhancing its US Injectables portfolio significantly. This acquisition adds 13 approved products and strengthens Hikma's R&D capabilities, bolstering its position as the second-largest supplier of generic sterile injectables in the US. Notable achievements include Custopharm's strong regulatory track record with four first-to-market FDA approvals. The acquisition was approved by the US Federal Trade Commission and positions Hikma for better service delivery to healthcare providers and patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Summary

Hikma Pharmaceuticals PLC announced that it has received preliminary approval from the US Federal Trade Commission (FTC) for its acquisition of Custopharm Inc. from Water Street Healthcare Partners. This follows the initial announcement made on September 27, 2021. With all necessary regulatory approvals now obtained, Hikma is moving forward to close the transaction and will provide further updates upon completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hikma Pharmaceuticals announced a $15 million investment from its venture capital arm, Hikma Ventures, in Activ Surgical, enhancing the Series B financing to a total of $60 million. Activ Surgical is developing AI-driven surgical technologies aimed at improving surgical outcomes. The ActivSight imaging module, which enhances visualization during surgery, has received FDA clearance and is set for broader availability in 2022. This investment will facilitate Activ Surgical's global launch, empowering surgeons with advanced decision-making tools and improving patient safety.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
Rhea-AI Summary

Hikma Pharmaceuticals’ venture capital arm, Hikma Ventures, has led an $11 million financing round for NuvoAir, a digital health company focusing on chronic disease management and decentralized clinical trials, particularly for respiratory conditions like COPD and asthma. This investment extends NuvoAir's Series A funding to $25 million in total. The funds will be used to enhance NuvoAir's platform, grow its team, and expand clinical services globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
-
Rhea-AI Summary

Hikma Pharmaceuticals announced the acquisition of Teligent Inc.'s Canadian assets for $45.75 million, expected to close by Q1 2022. This deal includes a portfolio of 25 sterile injectable products and 3 ophthalmic products, with 7 additional products in the pipeline, enhancing Hikma's entry into the Canadian market. Riad Mishlawi highlighted the strategic importance of this expansion, leveraging their marketing expertise to strengthen their North American presence. Teligent is currently under Chapter 11 Bankruptcy protection, necessitating this asset sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Hikma Pharmaceuticals PLC has launched Hikma 503B, a new outsourced sterile compounding business aimed at providing high-quality, ready-to-administer injectable medications tailored for US healthcare providers. The US market for outsourced compounded sterile injectable medications is expected to exceed $2 billion annually. Hikma is the second-largest supplier of generic injectables in US hospitals. The new facility in Dayton, NJ, enhances their capacity to meet rising demand and will comply with FDA's CGMP standards. Hikma 503B is set to operate nationwide by the end of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
Rhea-AI Summary

Gedeon Richter and Hikma Pharmaceuticals announced an exclusive licensing agreement for the commercialization of denosumab biosimilars in the US, referencing Prolia and Xgeva. Richter will handle product development and supply, while Hikma will manage FDA registration and US commercialization. The agreement includes an upfront payment and milestone payments totaling a double-digit million USD figure. This collaboration aims to enhance treatment options in the US market for osteoporosis and bone metastasis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
Rhea-AI Summary

Hikma Pharmaceuticals has announced a donation of 50,000 vials of Naloxone HCl Injection to the Opioid Safety and Naloxone Network (OSNN) Buyers Club, aiding in the critical shortage of this life-saving treatment for opioid overdoses in the US.

The donation originates from Hikma's sterile injectable manufacturing facility in Cherry Hill, NJ, and aligns with the company's Hikma Community Health initiative, focusing on addressing substance use disorder. Hikma aims to enhance access to naloxone amidst an ongoing overdose crisis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Hikma Pharmaceuticals has announced its agreement to acquire Custopharm Inc. for $375 million, with an additional $50 million contingent upon meeting commercial milestones. This acquisition enhances Hikma's portfolio, adding 13 approved products and bolstering its R&D capabilities through Custopharm's scientific team and laboratory. Custopharm is expected to generate over $80 million in revenue for the full year of 2021. The transaction is pending approval from the US Federal Trade Commission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
Rhea-AI Summary

Hikma Pharmaceuticals PLC has announced an exclusive US license agreement with FAES Farma S.A. to commercialize Bilastine tablets, an antihistamine for allergic rhinitis and urticaria. Hikma will obtain FDA regulatory approval and handle commercialization upon approval, providing upfront and milestone payments along with royalties to FAES. This partnership builds on an existing collaboration in the Middle East and North Africa, where Hikma is the exclusive licensee for Bilastine in 15 countries, aiming to enhance its presence in the US allergy market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of HIKMA PHARMS PLC S/ADR (HKMPY)?

The current stock price of HIKMA PHARMS PLC S/ADR (HKMPY) is $49.99 as of December 24, 2024.

What is the market cap of HIKMA PHARMS PLC S/ADR (HKMPY)?

The market cap of HIKMA PHARMS PLC S/ADR (HKMPY) is approximately 5.5B.

Where is Hikma Pharmaceuticals PLC headquartered?

Hikma Pharmaceuticals PLC is headquartered in the UK.

What is the focus of Hikma Pharmaceuticals PLC?

Hikma focuses on creating high-quality medicines and making them accessible to millions of people.

How long has Hikma Pharmaceuticals PLC been in operation?

Hikma has over 45 years of experience in the pharmaceutical industry.

In which regions does Hikma Pharmaceuticals PLC operate?

Hikma has a global presence across North America, the Middle East and North Africa (MENA), and Europe.

What is the commitment of Hikma Pharmaceuticals PLC?

Hikma is committed to providing a broad range of branded and non-branded generic medicines, shaping a healthier world for all communities.

HIKMA PHARMS PLC S/ADR

OTC:HKMPY

HKMPY Rankings

HKMPY Stock Data

5.53B
110.54M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
London